Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy CASI Pharmaceuticals stock | $1.06

Learn how to easily invest in CASI Pharmaceuticals stock.

CASI Pharmaceuticals Inc is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 144 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in CASI Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CASI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CASI Pharmaceuticals stock price (NASDAQ: CASI)

Use our graph to track the performance of CASI stocks over time.

CASI Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
Latest market close$1.06
52-week range$1.08 - $3.90
50-day moving average $1.28
200-day moving average $1.47
Wall St. target price$4.45
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.41

Buy CASI Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CASI Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CASI Pharmaceuticals price performance over time

Historical closes compared with the close of $1.06 from 2021-10-26

1 week (2021-10-21) -4.50%
1 month (2021-09-28) -13.11%
3 months (2021-07-28) -10.17%
6 months (2021-04-28) -45.08%
1 year (2020-10-27) -49.76%
2 years (2019-10-25) -68.73%
3 years (2018-10-26) 2.77
5 years (2016-10-27) 1.39

CASI Pharmaceuticals financials

Revenue TTM $22 million
Gross profit TTM $5.6 million
Return on assets TTM -18.41%
Return on equity TTM -50.72%
Profit margin -236.69%
Book value $0.68
Market capitalisation $152.4 million

TTM: trailing 12 months

Shorting CASI Pharmaceuticals shares

There are currently 2.5 million CASI Pharmaceuticals shares held short by investors – that's known as CASI Pharmaceuticals's "short interest". This figure is 10.6% down from 2.8 million last month.

There are a few different ways that this level of interest in shorting CASI Pharmaceuticals shares can be evaluated.

CASI Pharmaceuticals's "short interest ratio" (SIR)

CASI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of CASI Pharmaceuticals shares currently shorted divided by the average quantity of CASI Pharmaceuticals shares traded daily (recently around 3.4 million). CASI Pharmaceuticals's SIR currently stands at 0.72. In other words for every 100,000 CASI Pharmaceuticals shares traded daily on the market, roughly 720 shares are currently held short.

However CASI Pharmaceuticals's short interest can also be evaluated against the total number of CASI Pharmaceuticals shares, or, against the total number of tradable CASI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CASI Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CASI Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.022% of the tradable shares (for every 100,000 tradable CASI Pharmaceuticals shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CASI Pharmaceuticals.

Find out more about how you can short CASI Pharmaceuticals stock.

CASI Pharmaceuticals share dividends

We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.

Have CASI Pharmaceuticals's shares ever split?

CASI Pharmaceuticals's shares were split on a 1:11 basis on 30 June 2010. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.

CASI Pharmaceuticals share price volatility

Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $1.08 up to $3.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.3238. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).

CASI Pharmaceuticals overview

CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co.

Frequently asked questions

What percentage of CASI Pharmaceuticals is owned by insiders or institutions?
Currently 23.787% of CASI Pharmaceuticals shares are held by insiders and 33.421% by institutions.
How many people work for CASI Pharmaceuticals?
Latest data suggests 144 work at CASI Pharmaceuticals.
When does the fiscal year end for CASI Pharmaceuticals?
CASI Pharmaceuticals's fiscal year ends in December.
Where is CASI Pharmaceuticals based?
CASI Pharmaceuticals's address is: 9620 Medical Center Drive, Rockville, MD, United States, 20850
What is CASI Pharmaceuticals's ISIN number?
CASI Pharmaceuticals's international securities identification number is: US14757U1097
What is CASI Pharmaceuticals's CUSIP number?
CASI Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14757U109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site